T
he US blood supply is the safest it has ever been due to a combination of donor education, donor screening, and new laboratory test procedures. Risks of transfusion-transmitted viral infections are extremely low [1] [2] [3] : estimated to be I in 677,000 units for human immunodeficiency virus (HIV); 3 I in 641,000 for human Tlymphotropic virus (HTLV); 1 I in 103,000 for hepatitis C virus (HCV); 1 and I in 63,000 for hepatitis B virus (HBV).
1 Blood centers have implemented education programs and screening procedures aimed at reducing risk of transfusion-transmitted viral infections 4 and efforts are under way to improve behavioral screening of donors. Most infectious units are believed to be from donors who donate in the window period, the time between infection and detectability by screening tests. Thus, there has also been continuous effort to develop more sensitive and specific screening tests as exemplified by the introduction of HCV enzyme immunoassay (EIA) 2.0 in 1992, implementation of HIV-I p24 antigen screening and HCV EIA 3.0 in 1996, and introduction of HCV nucleic acid amplification testing in April 1999. 5 Monitoring time trends in infectious disease rates in the blood donor population provides a mechanism to assess the safety of the blood supply and the effectiveness of donor deferral criteria and other screening measures. Changes in blood donor infectious disease rates may also reflect changes in population risks. For example, acquired immunodeficiency syndrome (AIDS) incidence rates (IRs), while decreasing in homosexual men, increased in women and racial and ethnic minorities in the mid 1990s. We evaluated changes in rates of transfusion-transmissible viral infections (TTVIs) between 1991 and 1996 using test data collected on all allogeneic (community, directed, and apheresis) donations given at 5 US blood centers taking part in the National Heart, Lung, and Blood Institute-sponsored Retrovirus Epidemiology Donor Study (REDS). This study represents an additional 3 years of data compared with a prior report on the incidence of viral markers, 1 allowing analysis of trends.
METHODS
Data on donation type and date, demographic characteristics (age, sex, race/ ethnicity, and education level), and serological test results have been collected by REDS on an ongoing basis since 1991 at 5 blood centers: the American Red Cross (ARC) Biomedical Services Greater Chesapeake and Potomac (Baltimore, MD, and Washington, DC), Southeastern Michigan (Detroit), and Southern California (Los Angeles) Regions; the Blood Centers of the Pacific in San Francisco; and the Oklahoma Blood Institute in Oklahoma City. Westat (Rockville, MD) serves as the coordinating center. REDS compiles information on approximately 8% of all US allogeneic collections. The REDS protocol was approved by the Institutional Review Board at each center.
To assess changes in rates of TTVIs from 1991 to 1996, we analyzed data on 5.9 million allogeneic donations from 1.9 million donors between 1991 and 1996. Serological tests were done according to standard operating procedures at each center and included the following: tests for antibodies to HIV type 1 (types 1 Donors, 1991 Donors, -1996 and 2 after March 1992) and tests for HTLV antibody (Ab), hepatitis B surface antigen (HBsAg), hepatitis B core Ab, and HCV Ab.
Trends in Incidence and Prevalence of Major Transfusion-Transmissible Viral Infections in US Blood
Confirmatory tests included the HIV-1 Western blot (WB) assay (Cambridge Biotech Corp, Worcester, Mass) or the recombinant immunoblot assay (RIBA, Chiron Corporation, Emeryville, Calif) for HIV; the RIBA 2.0 (Chiron) for HCV; and the monoclonal neutralization assay (Abbott Laboratories, Abbott Park, III) for HBsAg. The confirmatory algorithms for HTLV varied by blood centers and changed over time. At ARC centers, both an in-house HTLV viral lysate WB and Cambridge p2 I e EIA were used as confirmatory tests from January 1991 to November 1993 with the presence of p24 on WB and a p2 I e EIA sample/cutoff ratio exceeding 6.0 needed for HTLV confirmation. Radioimmune precipitation assays were performed if the combined results of the first 2 assays were indeterminate. The 6.0 EIA sample/ cutoff ratio (rather than a sample/ cutoff ratio of 1.0, which is the usual interpretation of a positive EIA) was chosen to minimize falsepositive reactivity to the HTLV-I from HTLV-II. If HTLV type was discordant by interpretation of relative strengths of WB bands vs peptide testing, cells from that donor (if available) were sent for HTLV DNA testing by PCR. Eightynine percent of 702 WB-positive allogeneic samples were evaluated using this protocol; we identified 57 HTLV peptide EIA-and PCRnegative donations (presumed false positive), with 52 occurring at ARC centers and 5 at non-ARC centers. For HBsAg, 92 allogeneic donations were identified as possibly falsepositive because 1 of their 3 EIA optical densities was 0.2 or less and their Ab to hepatitis B core antigen was negative.
9 Kleinman etal 9 determined that at least 70% of HBsAg-neutralized positive tests with these characteristics are negative on HBV DNA PCR and are therefore presumed to be falsepositive.
All analyses were conducted using the number of true-positive tests i. II . Of the HBV incident subjects, 70% were assumed to be transient HBsAg carriers with a 63-day antigenemia period, and 5% were assumed to be chronic HBsAg carriers.
11,12
A Pearson X 2 test of a common IR among the five 2-year intervals was used to test whether any change in IRs could be detected. 13 Because this statistic requires independent categories, person-years and the number of incident cases in each 2-year interval were further subcategorized into the following: (1) person-years and number of incident cases in common with the preceding 2-year interval, (2) person-years and number of incident cases unique to the 2-year interval, and (3) person-years and number of incident cases in common with the subsequent 2-year interval. (1994 -1996) and the average of the remaining HTLV prevalence estimates. The prevalence estimates for the ARC centers between 1994 and 1996 were statistically equivalent (P=.38) , and the prevalence estimates for ARC (1991 -1993) and non-ARC centers (1991 non-ARC centers ( -1996 We observed a corresponding decrease in first-time non-Hispanic white donors, with 80.8% (n = 169 215) of donors being white in 1991 vs 70.1% (n=119568) in 1996.
RESULTS

First-Time Donors
Hepatitis infections were detected at an order of magnitude greater frequency than were retroviral infections among first-time donors (FIGURE 1). We observed a gradual decline in HCV prevalence in firsttime donors, with estimates decreasing from 0.63% in 1992 to 0.40% in 1996 (P<.001, Figure 1 ). In contrast, the proportion of HBsAg-positive first-time donors (about 0.2%) remained relatively constant (P=.36). The prevalence estimates shown in Figure 1 were calculated treating presumed HBsAg false-positive results as negatives, but similar estimates were obtained without this adjustment.
The prevalence of HIV decreased after 1992 by a factor of 1.5 to 2.0, with estimates varying from 0.030% to 0.028% in 1991-1992 to 0.018% to 0.015% in 1993-1996 (P=.0001 comparing 1991-1992 with 1993-1996 , P for trend = .006 for [1991] [1992] [1993] [1994] [1995] [1996] . The apparent increase in HTLV prevalence in 1994-1996 compared with earlier years (from about 0.035% to 0.046%), although not significant (P =. 10, Figure 2 ), warranted further investigation. We calculated the proportion of HTLV donors who were HTLV-I and HTLV-II positive to assess whether the trends differed by virus type. Furthermore, because the revision in HTLV confirmatory testing that occurred at the ARC centers in November 1993 (see "Methods") could have resulted in detection of a larger number of false-positive results, we also compared the proportion of HTLV-positive donors at ARC centers with that at other REDS centers. As shown in Figure 2 , HTLV-II is about 3 times more prevalent than HTLV-I in first-time blood donors (24-33 per 100 000 for HTLV-II vs 6-15 per 100 000 for HTLV-I). The average HTLV prevalence estimate obtained at ARC centers between 1994 and 1996 was significantly higher (P<.001, FIGURE 2) than the average of the remaining HTLV prevalence estimates (ie, prevalence at non-ARC centers between 1991 and 1996 and prevalence at ARC centers from 1991-1993).
Repeat Donors
A total of 903,228 repeat donors were included in the analysis; 52% were men and 84% were nonHispanic white. Forty percent had a college degree or higher level of education, and 38% were younger than 35 years (as of December 31, 1996) . The percentage of Hispanic and Asian repeat donors increased from 1991 to 1996 (3.6% to 6.0% for Hispanics; 2.0% to 2.7% for Asians).
The overall IRs per 100,000 person years (and 95% Cls) for 1991 to 1996 were 2.92 (2.26-3.70) 1991 -1992, 1992 -1993, 1993 -1994, 1994 -1995, and 1995 -1996 were the following, respectively: HIV:11, 14, 11, 4, 6; HTLV: 3, 4, 5, 9, 8; HBsAg: 20, 21, 14, 8, 10; and HCV (EIA 2.0 only): 16, 11, 12, 9 follows, respectively: 421,338; 416,515.3; 405,102.6; 410,882.5; and 400,801.6 . The number of intervals was 1014788, 1037610, 1027354, 1040999, and 1026145 for the same time periods, respectively. Although IRs appeared to increase for HTLV (from 0.71 to 2.00) and decrease for HIV (from 2.61 to 1.50) and HBV (from 13.9 to 6.9), these trends were not statistically significant (P =. 20 for HTLV, P =. 14 for HIV, and P =. 17 for HBV). Trend was also not statistically significant for HBV calculations conducted with presumed false-positive results considered positive, with HBV IR estimates varying from 21.6 to 13.9 (P =. 74). Hence, there was no detectable pattern between 1991 and 1996, with IRs remaining stable for both retroviruses and hepatitis B and C. The small number of incident cases prevented us from evaluating trends in HTLV incidence by type or by center (ARC vs non-ARC).
COMMENT
All blood donors undergo predonation screening that has evolved through the years. In the REDS blood centers, HIV prevalence decreased from 0.03% (1991) (1992) to less than 0.02% (1993) (1994) (1995) (1996) in first-time donors. In contrast, the prevalence of HIV infection in the US population increased between 1984 and 1992, with 0.3% of the US population (about 1 million people) estimated to be infected as of 1992.
18 Firsttime donor HIV-1 prevalence at the beginning of this study was about one tenth that of the general population, with a further 50% reduction during the course of the study. This decline in first-time donors may reflect (1) a decline in HIV prevalence in the segment of the population recruited to donate, (2) the continuing increase in the proportion of the population that has been tested for HIV by clinics or their physician, or (3) improved effectiveness of education and screening procedures leading to increased deferral of persons reporting high-risk behaviors.
The most common TTVI in first-time donors is HCV. We saw a decrease in prevalence from 0.63% in 1992 to 0.40% in 1996, consistent with a prior report. 19 The prevalence of HCV was estimated at 1.8% in the general population for 1988-1994 20 25 Prevalence of HBV was estimated at 3.6% in NHANES II and 13.7% vs 11. 9% in blacks. These rates are at least 15-fold higher than those for first-time donors.
Since HBV appears to be stable since the late 1970s in the general and blood donor populations, it is unlikely that changes in predonation screening in the 1980s and 1992 had a major impact on deferral of first-time donors infected with hepatitis B. Although current criteria are likely effective in screening out some persons at high risk for hepatitis B, it is difficult to develop screening criteria sensitive enough to effectively reduce the prevalence of hepatitis B in firsttime blood donors and specific enough to avoid unnecessary deferral of healthy donors (no risk factor can be identified in 30% to 40% of HBV cases). 26 A widespread hepatitis B immunization program in effect in the United States since late 1992 may lead to a decrease in hepatitis B prevalence in the future 21 in first-time donors (by preventing early childhood infection and providing immunity for adolescents and adults before they engage in high-risk behaviors).
On introduction of HTLV screening in 1989, 0.014% to 0.021% of all donations were confirmed positive for HTLV-I or II.
27 Seroprevalence rates are higher in high-risk groups such as prostitutes (7%), sexually transmitted disease clinic patients (0.4%), and homosexual men (0.1%).
28 A substantial proportion of HTLV infections in the United States is represented by HTLV-II; it is relatively highly prevalent in IDUs (0.4%-17.6%). 29 In our study, HTLV prevalence in first-time donors ranged from 0.035% in 1991 to 0.046% in 1996, with significantly higher prevalence at ARC centers after the introduction of a new confirmatory test algorithm 30 in November 1993. Although a real increase in HTLV infection in donors at the 3 ARC centers in 1994-1996 cannot be excluded, we believe that a more likely explanation for this increase is the change in the ARC testing algorithm for the following reasons: false-positive results have been previously reported with this algorithm 30 ; the increase in confirmed positives was confined to ARC centers in 1994-1996; most false-positive results identified in this analysis occurred at the 3 ARC centers after November 1993 (47/57) and we suspect that our stringent criteria did not capture all false-positive results (about 11% of WB-positive allogeneic samples could not be evaluated and we interpreted the few [n = 16] EIA-positive and PCR-negative results as HTLVinfected); there was no obvious geographical pattern to the increase (we observed an increase at the ARC center located on the West Coast but not at the non-ARC center located in the same geographical area); and the HTLV screening assays at ARC centers were no more sensitive than those used at non-ARC centers.
Repeat donors must not only deny risk behaviors at their predonation screening, but must have tested negative on their prior donation. Thus, TTVI rates in repeat donors would be expected to be lower than in first-time donors. It is also likely that most repeat donors will not suddenly engage in a new high-risk behavior. Our results from donors who gave at least 2 allogeneic donations in 2 years confirm that IRs as described previously 1,2 for these viral infections are small. Incidence rates calculated for each overlapping 2-year interval did not statistically significantly differ from one another; thus, IRs and consequently transfusiontransmitted risks have remained stable.
This low level of TTVI risk in repeat donors could in part be explained by some failure in the screening process. An estimated 1.9% of acceptable donors surveyed in 1993 admitted to a risk factor that should have resulted in deferral if it had been reported at time of donation.
31
Units given by these high-risk donors are more likely to be infectious and may not be detected by screening tests (window-period units), thereby raising TTVI risk.
The small number of seroincident donors shows the difficulty of studying rare events and may have prevented us from finding significant trends in IRs or evaluating IRs for HTLV by type or by ARC vs non-ARC centers. The low number of prevalent and incident cases also precluded development of valid models to assess the influence of demographics. To avoid bias that could be introduced by varying sensitivities of different generation HCV assays, we considered only the data collected following implementation of the second generation EIA. Hence, for HCV, the 1992-1993 and 1995-1996 IRs, only reflect the rates in donors who gave at least 2 donations during a portion of these intervals.
CONCLUSION
The lower prevalence estimates in first-time donors vs the general population suggest that screening for behavioral risk factors associated with these major viral infections is effective. Using a combination of sensitive and less sensitive HIV-1 ElAs, Janssen et al 32 estimated that 12.6% of HIV-1 infected first-time donors were recently infected. Thus, the recent downward trend in HIV and HCV prevalence in first-time donors may translate into a lower number of infectious window period units, indicating that the safety of the US blood supply continues to improve. Although these data are reassuring, further improvement in behavioral screening is desirable. Although some strategies may be difficult to implement in light of chronic blood shortages, approaches to improve deferral procedures include the following: (1) increasing education about and awareness of risk factors and the importance of safe blood donations in the general population, (2) States, 1984 to 1992 . JAMA. 1996 276:126-131. 19 . Alter HJ, Conry-Cantilena C, Melpolder J, et al. Hepatitis C in asymptomatic blood donors. Hepatology. 1997; 26(3 suppl 1) :29S-33S. States, 1988 through 1994 . N Engl J Med. 1999 341:556-562. Rep. 1998; 47 (RR-19) States, 1976 -1994 . J Infect Dis. 1998 178:954-959. States. Gastroenterol Clin North Am. 1994; 23:437-455. States, 1989 . MMWR Morb Mortal Wkly Rep. 1990 39:915, 921-924. Physician. 1989; 40:189-195. We have seen BSE clinical signs and pathological changes in one recipient of blood from a BSE-infected animal, and we regard this finding as sufficiently important to report now rather than after the study is completed, several years hence. The blood donation resulting in transmission of BSE to the recipient was 400 mL of whole blood taken from a healthy sheep 318 days after oral challenge with BSE. BSE subsequently developed in this donor animal 629 days after challenge, indicating that blood was taken roughly half way through the incubation period. 610 days after transfusion, the transfused sheep (D505) itself developed typical TSE signs: weight loss, moderate pruritus, trembling and licking of the lips, hind- EDITOR'S NOTE: The Lancet's article on transmission of TSE by transfusion in sheep has triggered a flurry of discussion. Readers would be well advised to also read the editorial accompanying this article where Paul Brown of the Laboratory of Central Nervous System Studies, National Institutes of Health, questions the validity of this preliminary study based on one animal. Brown states "science should not be driven to what in certain medical quarters might be termed a premature emission through fear of media misrepresentation." (see The Lancet 2000; 356:955-956) In the United Kingdom, the National Blood Authority revealed that 7 out of the 82 New Variant Creutzfeldt-Jakob Disease (nvCJD) victims were blood donors and announced that a total ban on British plasma may by instituted. Australia quickly reversed a decision not to ban British donors and announced that they will impose restrictions similar to other countries.
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This article reported findings that sheep in the early, symptom-free stages of mad cow disease can pass the brain-wasting ailment to other sheep through blood transfusions. Though these findings raise the possibility the human form of the disease could be transmitted through blood transfusions, researchers cautioned the risk was still "theoretical''. No cases have been recorded of humans becoming infected from a blood transfusion.
In response to the nvCJD threat, British blood banks have introduced precautions to reduce the risk of contaminated blood supplies, including filtering out all white blood cells which could potentially carry the infection and importing plasma from countries where there is no evidence of Creutzfeldt-Jakob disease, the human form of the fatal mad cow disease.
Some 82 cases of the new variant Creutzfeldt-Jakob disease have been confirmed in Britain. The disease first surfaced in the mid-1990s, about ten years after after a veterinarian discovered Britain's first BSE-infected cattle herd. Scientists believe people contract new variant Creutzfeldt-Jakob disease by eating beef infected with bovine spongiform encephalopathy. The disease can be confirmed only by examining the brain after death.
Since the British outbreak, Bovine Spongiform Encephalopathy has also been found in cattle in Portugal and in smaller numbers in Belgium, Denmark, France, Ireland, Luxembourg, the Netherlands, and Switzerland. limb ataxia, and proprioceptive abnormalities. This is the first experimental transmission of BSE from sheep to sheep and so we have nothing with which to compare this incubation period directly. In crossspecies transmissions, bovine BSE injected intracerebrally gives incubation periods of about 450 days in these sheep, 5 and the donor animal had an oral BSE incubation period of 629 days (see above). There are no similar data available on other infection routes. Immunocytochemistry with the antibody BG4 on tissues taken from sheep D505 showed widespread PrP SC deposition throughout the brain and periphery. Western blot analysis of brain tissue with the antibody 6H4 showed that the PrP SC protein had a glycoform pattern similar to that of experimental BSE in sheep and unlike that of UK natural scrapie (figure), indicating that the TSE signs resulted from transmission of the BSE agent. All other recipients of transfusions and positive and negative controls are alive and healthy. The positive controls, which involve a species barrier, are expected to have lengthy incubation periods. With one exception, all transfused animals are at earlier stages post-transfusion than was D505. The exception is a sheep which is healthy 635 days after transfusion with BSEblood donated at less than 30% of the BSE incubation period of the donor sheep.
Although this result was in only one animal, it indicates that BSE can be transmitted between individuals of the same species by whole-blood transfusion. We have no data on blood fractions or on levels of infectivity in blood of preclinical vCJD cases, but whole blood is not now used in UK transfusions. The presence of BSE infectivity in sheep blood at an early stage in the incubation period suggests that it should be possible to identify which cells are infected, to test the effectiveness of leucodepletion, and to develop a diagnostic test based on a blood sample.
Editor's Notes
New infectious disease testing: Nucleic acid (gene) amplification testing (NAT) allows for early detection of infectious diseases (such as HIV and hepatitis C (HCV)) in blood by detecting the genetic material of viruses. More than 90 percent of all blood components in the United States are currently tested by NAT under an FDA-approved investigational new drug (IND) protocol. In the first 15 months of implementation, NAT has detected and intercepted four HIV-positive donations and more than 57 HCV-positive donations. This means that roughly 150 potential HCV and HIV infections were prevented as a result of NAT.
Leukoreduction technologies:
Several studies have shown that removing the leukocytes or white cells from blood components -a process commonly referred to as leukoreduction -can reduce the frequency and severity of complications from blood therapy.
These important blood safety measures are costly. Leukoreduction and NAT are estimated to add over 40 percent to the cost of blood. In the future, additional life-saving technologies, such as viral inactivation, are likely to add to the cost of transfusion therapies.
Not-for-profit Blood Centers and Transfusion Services Cannot Absorb Added Costs.
Not-for-profit blood collection centers operate in the same managed care environment as our hospital customers. As a result, blood centers must charge hospitals for the blood products and services we provide to recover the costs associated with collecting, testing, processing, storing
American Red Cross Advocates Enhanced Medicare Inpatient Reimbursement
TO ASSURE PATIENT ACCESS TO SAFEST POSSIBLE BLOOD SUPPLY
and distributing blood for patients in need. Hospitals, in turn, must get timely reimbursement for these lifesaving and life-enhancing products and services. Currently, there is a lag of up to three years between the time that an FDA-recommended procedure is implemented and the time the hospital is adequately reimbursed.
Legislation to Provide Fair Reimbursement Needed to Ensure Patient Access to Highest Quality Blood Therapies
Fair and adequate Medicare reimbursement is necessary to ensure patient access to the safest possible blood. Unfortunately, the current system by which the Health Care Financing Administration (HCFA) determines inpatient reimbursement rates does not account for these safety improvements in a timely manner.
In 1999, Congress and the Administration acknowledged the importance of supporting blood safety advancements through fair Medicare reimbursement in the outpatient setting. However, the vast majority of blood is supplied in the inpatient setting. Thus, it is critical that inpatient reimbursement policies also be adjusted to reflect increases in the cost of these products and services.
Recognizing the importance of patient access to a safe and adequate blood supply, Congress should enact legislation that assures fair Medicare payments for inpatient blood products and services. The American Association of Blood Banks, America's Blood Centers and the American Red Cross are urging Congress to adopt legislation that:
1 Increases the Medicare hospital inpatient "market basket" by 0.37 percent to cover the added costs associated with recent blood safety enhancements that are FDA recommended and/or adopted as the standard of care. This increase should be provided on an annual basis until a longer-term remedy is implemented (see below);
2 Direct the Secretary of Health and Human Services, by no later than August 1, 2002, to revise the market basket index to include a separate expense category for blood and transfusion-related products and to utilize an index measuring changes in the input prices for such products that are specific to the hospital industry; and Direct MedPAC to perform an analysis of the increased costs incurred by hospitals in providing inpatient hospital services since the inception of the DRG payment system that are attributable to the adoption of new blood safety measures; the extent to which the prospective payment system provides adequate and timely recognition of such increased costs; the prospects for future cost increases in providing these services that are attributable to new blood safety measures during the next ten years; and, the feasibility and desirability of establishing mechanisms under such a payment system to provide for more timely and accurate recognition of the costs of such blood safety measures.
Legislation is necessary to restore adequate payment to hospitals, which, in turn, will ensure patient access to state-of-the-art blood products and services and the safest possible blood supply.
Recognized by Congress, the public, the federal government and the blood banking community, patient access to the safest possible blood supply is a national public health priority. The blood banking and transfusion medicine communities work diligently to assure that safety improvements are implemented in a timely manner. Two recent initiatives have been introduced to increase the safety of the blood supply. However, these measures significantly increase the cost of blood products and services for both hospitals and blood banks: 
Inventory Being Closely Monitored
Fresh Frozen Plasma (FFP):
1 FFP is the fluid portion of blood that is separated and frozen at -18° C or colder within 8 hours after collection of whole blood if the anticoagulant solution is CPD, CP2D, or CPDA-1. Plasma collected in ACD or 2-3% Sodium Citrate (i.e., by apheresis) must be frozen within 6 hours of collection to be considered FFP.
FFP contains plasma proteins including all coagulation factors. By definition, each mL of idealized plasma contains 1 international unit (IU) of each coagulation factor. Since the volume of this component is generally between 180 and 300 mL, a unit of FFP usually contains about 200 IU of each coagulation factor. The amount of coagulation factor activity in one unit of FFP equals approximately 7% of the coagulation factor activity in a 70 kg patient. FFP frozen at -18° C outdates at 1 year. Discussion: There is little difference in the levels of labile coagulation factors between FFP and Plasma (Frozen Within 24 Hours of Collection). Factor V levels studied were essentially the same in plasma frozen at 8 hours and at 24 hours after collection.
Plasma (Frozen
2,3 On average, the major difference is a 25% reduction of Factor VIII.
1 {Factor VIII measured in plasma held at 4ºC for 8 hours after collection was 84% ± 16% versus plasma held at 4ºC for 24 hours after collection which was 64% ± 13%. 2 Another study shows the percentage of Factor VIII:C at 8 hours holding time was 89.8% ± 1.9% versus 75.9% ± 2.4% at 24 hours. Background:Refractory alloimmunized patients may be managed with platelets (plts) that are HLA-matched or crossmatched (XM). Alternatively, one may select plts using HLA antibody specificity (Antibody Specificity Prediction [ASP] method), but the effectiveness of this method has not been extensively evaluated.
Study Design:HLA antibody specificity was determined using an antihuman globulin enhanced microlymphocytotoxicity test and a computer program. Plts transfused were HLA-matched (A or BU matches), XM, selected by the ASP method, or randomly selected. The % predicted recovery (PPR) was calculated using the number of plts transfused, and pretransfusion and posttransfusion counts obtained at 0-4, 4-12 or 12-24 hours. We evaluated 1,621 transfusions in 114 patients. The mean PPR was compared for the 4 plt products using repeated measure analysis of variance methods controlling for 13 clinical and laboratory covariates. Background: Piperacillin, a semi-synthetic antibiotic related to penicillin, has only recently been described as causing immune hemolytic anemia (IHA). In one case, the drug-dependent antibody (Ab) was primarily IgM and reacted with drug-treated RBCs as well as untreated (UT) RBCs in the presence of drug ("immune complex" method). In the 2nd case, serological information was scanty.
Case Study: A 29-year-old man with cystic fibrosis, and a history of previous penicillin therapy, developed hemolytic anemia (Hb 13 3.9g/dL; bilirubin 0.7 3.6 mg/dL) after 10 days of piperacillin therapy (4000 mg IV q 6 hrs). The direct antiglobulin test (DAT) was positive (anti-IgG and anti-C3 =2+), but serum and an eluate were nonreactive. Conclusion: This is the 3rd example of anti-piperacillin to cause drug-induced IHA. This example differed from the one well-described case in that this patient's Ab reacted only by the "immune complex" method and appeared to be IgG. As piperacillin is commonly used in the treatment of cystic fibrosis, anti-piperacillin should be considered whenever these patients develop hemolytic anemia or a positive DAT. Results:See table below. For 16 patients the number of HLAmatched donors in a file of 7,000 HLA-typed donors ranged from 0-8 (median =2) whereas by ASP the range was 11-4,258 (median =788).
Results
Conclusions:ASP-selected plts were as effective as XM or HLAmatched and were statiscally significantly superior to randomly selected. Also, the ASP method provides a markedly expanded pool of effective plt donors for immunized patients.
Selecting platelet donors for refractory patients using HLA antibody specificity PRODUCT 
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